Type2diabetes
Metabolic Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
HM
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Hua MedicineDorzagliatin tablets
Vicore PharmaC21
Clinical Trials (2)
Total enrollment: 2,011 patients across 2 trials
A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes
Start: Dec 2023Est. completion: Apr 20262,000 patients
Phase 4Recruiting
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
Start: Mar 2023Est. completion: Jun 202311 patients
Phase 1Completed
Related Jobs in Metabolic Diseases
Manager, Patient Safety and Pharmacovigilance Operations
Kailera Therapeutics
Waltham, Massachusetts
11h ago
Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV
Amgen
California - San Francisco, US
Yesterday
(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)
Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago
Computational Chemist
Topos Bio
San Francisco Office
2d ago
Associate Director, Legal Operations & Contracts Management
Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr
Application & Integration Architect
Roche
Indianapolis
5d ago
$106K - $196K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,011 patients
2 companies competing in this space